CLK1 and Alzheimer disease: Concretely, we performed a detailed computational study for the development of specific tau (GSK3β and CK1δ) and dual-specificity (DYRK1A and CLK1) protein kinase inhibitors, starting from marine natural products, meridianin F and kororamide A, until achieving the rational design of indole scaffolds derivates as possible ATP-competitive kinase inhibitors for the treatment of AD.